Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV

Led by a team of veterans from Alios BioPharma and Janssen, Aligos Therapeutics raised $125 million in a series B round to bring three of its HBV therapies to the clinic this year. Aligos thinks that in combination, the trio of modalities could lead to the development of a functional HBV cure under one roof.

Wellington Management and an undisclosed global investment management firm led the round. Other new investors include funds managed by Janus Henderson Investor, Boxer Capital of

Read the full 794 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE